TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

TG Therapeutics, Inc.NASDAQ: TGTX

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables dips below year-ago levels

Q3 FY2026 accounts receivables of $15.26M (cash outflow) fell 55.0% year over year, behind the +1.2% change in trailing-twelve-month accounts receivables. Sequentially, it rose 60.3% from the prior quarter.

Context

  • Accounts receivables amounted to 28.6% of revenue in FY2025, up 4.9 pp from a year earlier.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -55.0% toward the trailing-twelve-month pace of +1.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$15.26M+60.3% QoQ
Last fiscal yearDec 2025
-$176.44M+125.9% YoY
LTMSep 2026
-$151.44M+1.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.0%——
1 year+125.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(176.44M) USD
Year-over-year change
-125.9%

Accounts Receivables vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.2% is the 5th highest of 6, against a peer median of +103.5%.
  • Accounts receivables amounts to 16.9% of revenue for TGTX, versus a peer median of 0.7%.
TGTX Competitors
Accounts Receivables for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$189.32M USD—-57.2%4.6%
TGTXTG Therapeutics, Inc.LTM Sep 2026$151.44M USD+1.2%—16.9%
XNCRXencor, Inc.LTM Jun 2026$8.54M USD+12.9%-8.0%8.1%
ADCTADC Therapeutics S.A.LTM Mar 2026$516.86K USD+106.0%-41.0%0.7%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$265K USD-134.8%+95.9%236.6%
MGNXMacroGenics, Inc.LTM Mar 2026$117K USD+103.5%-41.7%0.1%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$36K USD+167.9%——
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
ADAGAdagene Inc.LTM Jun 2024$0 USD——0.0%
Peer median (excluding TGTX) —+103.5%-41.0%0.7%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(348.1M)(198.34M)12.67M23.38M447.18M
Depreciation & Amortization494K515K423K280K244K
Deferred Income Tax517K000(348M)
Stock-Based Compensation61.27M19.19M37.93M42.54M64.67M
Change in Working Capital(12.22M)(1.65M)(84.66M)(109.3M)(194.54M)
Accounts Receivables(1.39M)1.39M(51.09M)(78.09M)(176.44M)
Inventory(15.99M)0(36.94M)(66.85M)(33.45M)
Accounts Payables15.99M(11.01M)192K055.88M
Other Working Capital(10.83M)7.97M3.18M35.65M(40.52M)
Other Non-Cash Items2.4M4.11M2.22M2.58M5.67M
Operating Cash Flow(295.63M)(176.17M)(31.41M)(40.52M)(24.77M)
Capital Expenditures(401K)(14K)0(45K)(214K)
Acquisitions (Net)(69K)20M000
Purchases of Investments(55.53M)(107.27M)(146.88M)(311.89M)(223.49M)
Sales of Investments55.6M87.28M96.23M310.9M237.5M
Other Investing Activities69K(20M)000
Investing Cash Flow(332K)(20.01M)(50.65M)(1.04M)13.8M
Debt Repayment40M(975K)25M137.26M0
Common Stock Issued2.22M584K46.3M01.51M
Common Stock Repurchased000(8.76M)(91.24M)
Dividends Paid00000
Other Financing Activities(800K)01.41M25K0
Financing Cash Flow41.42M(391K)72.71M128.53M(89.73M)
Effect of Forex Changes00000
Net Change in Cash(254.55M)(196.57M)(9.36M)86.97M(100.7M)
Free Cash Flow(296.04M)(176.18M)(31.41M)(40.56M)(24.99M)

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.